NCT06629779 2026-04-16
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
Clinical Trials
15 trialsNCT06318273 2026-04-08
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
AbbVie
Phase 1 Recruiting
NCT07287150 2026-04-08
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06531499 2025-12-31
RADIODOSE
Novartis
Phase 1 Recruiting
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02405858 2025-02-03
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
Janssen Pharmaceutical K.K.
Phase 4 Completed
NCT04986423 2025-01-24
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 2 Recruiting
NCT02116582 2024-12-06
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc
Phase 4 Completed
NCT03414034 2024-11-07
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology
Phase 2 Completed
NCT04408924 2024-06-25
CYCLONE 1
Eli Lilly and Company
Phase 2 Completed
NCT04419402 2024-02-07
ENZA-p
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02125357 2020-08-07
Sequencing Abiraterone and Enzalutamide in mCRPC
British Columbia Cancer Agency
Phase 2 Completed
NCT03137758 2020-03-09
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Pellficure Pharmaceuticals, Inc
Phase 1 Terminated
NCT02091531 2019-11-21
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed